Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden liver danger in Cushing's syndrome may reverse after cortisol cure

NCT ID NCT05881005

Knowledge-focused Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study looks at how common fatty liver disease is in people with Cushing's syndrome, a rare condition caused by too much cortisol. Using MRI and FibroScan, researchers will measure liver fat at diagnosis and again one year after cortisol levels return to normal. The goal is to see whether fatty liver goes away once the underlying hormone problem is fixed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hepatic MRI and FibroScan
What this could lead to
If successful, this study could clarify how often fatty liver complicates Cushing's syndrome and whether curing the cortisol excess reverses liver fat, guiding future treatment monitoring.
What could go wrong
This is an observational study with no treatment being tested, so it cannot prove that any intervention works. The sample size is modest (100 people), and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 years * Active Cushing's syndrome Exclusion Criteria: * Other common causes of chronic liver disease (HBV, HCV, haemochromatosis, alcohol) * Contraindication to MRI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cushing syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cushing syndrome fatty liver disease metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cushing syndrome Fatty liver disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital, Angers

    RECRUITING

    Angers, 49000, France

  • University Hospital, Bordeaux

    RECRUITING

    Bordeaux, 33604, France

  • University Hospital, Brest

    RECRUITING

    Brest, 29609, France

  • University Hospital, Grenoble

    RECRUITING

    Grenoble, 38043, France

  • University Hospital, Lille

    RECRUITING

    Lille, 59800, France

  • University Hospital, Nancy

    RECRUITING

    Vandœuvre-lès-Nancy, 54500, France

  • University Hospital, Nantes

    RECRUITING

    Nantes, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.